一项关于活减毒水痘带状疱疹病毒疫苗的 I- II 期研究，旨在增强既往患过水痘的人类免疫缺陷病毒感染儿童的免疫力。
A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.
机构信息
Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
出版信息
Pediatr Infect Dis J. 2009 Jul;28(7):653-5. doi: 10.1097/INF.0b013e3181998f06.
Abstract
Herpes zoster, may be severe and recurrent in HIV-infected children. We determined the safety and immunogenicity of live attenuated varicella-zoster virus (VZV) vaccine in 46 HIV-infected children who had experienced varicella. There were no serious adverse events. Two years after vaccination 82% of subjects remained VZV-antibody positive and 60% had VZV-specific cell-mediated immunity. No child developed herpes zoster.
摘要
带状疱疹在 HIV 感染儿童中可能较为严重且反复发作。我们在 46 例曾患水痘的 HIV 感染儿童中评估了减毒活水痘-带状疱疹病毒（VZV）疫苗的安全性和免疫原性。未发生严重不良事件。接种疫苗 2 年后，82%的受试者仍保持 VZV 抗体阳性，60%具有 VZV 特异性细胞介导免疫。无儿童发生带状疱疹。
相似文献
1
A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella.
Pediatr Infect Dis J. 2009 Jul;28(7):653-5. doi: 10.1097/INF.0b013e3181998f06.
2
The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children.
Pediatr Infect Dis J. 2011 Apr;30(4):320-4. doi: 10.1097/INF.0b013e3181fe0868.
3
Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults.
Hum Vaccin. 2010 Apr;6(4):318-21. doi: 10.4161/hv.6.4.10654. Epub 2010 Apr 15.
4
Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older.
Vaccine. 2000 Jun 15;18(25):2915-20. doi: 10.1016/s0264-410x(99)00552-6.
5
Varicella Virus Vaccination in the United States.
Viral Immunol. 2018 Mar;31(2):96-103. doi: 10.1089/vim.2017.0136. Epub 2017 Nov 27.
6
Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection.
J Infect Dis. 1997 Dec;176(6):1496-500. doi: 10.1086/514147.
7
Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus.
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):791-8. Epub 2012 Oct 17.
8
A fresh look at varicella vaccination.
Hum Vaccin Immunother. 2025 Dec;21(1):2488099. doi: 10.1080/21645515.2025.2488099. Epub 2025 Apr 15.
9
Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine.
BMJ Open. 2017 Sep 21;7(9):e017391. doi: 10.1136/bmjopen-2017-017391.
10
The current status of live attenuated varicella vaccine.
Arch Virol Suppl. 2001(17):1-6. doi: 10.1007/978-3-7091-6259-0_1.
引用本文的文献
1
Immunogenicity and safety of live attenuated and recombinant/inactivated varicella zoster vaccines in people living with HIV: A systematic review.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2341456. doi: 10.1080/21645515.2024.2341456. Epub 2024 Apr 22.
2
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.
PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016.
3
A literature review on the patients with autoimmune diseases following vaccination against infections.
Hum Vaccin Immunother. 2015;11(9):2274-80. doi: 10.1080/21645515.2015.1009337.
4
Successes and challenges in varicella vaccine.
Ther Adv Vaccines. 2014 Mar;2(2):39-55. doi: 10.1177/2051013613515621.
5
Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.
PLoS Med. 2013;10(4):e1001420. doi: 10.1371/journal.pmed.1001420. Epub 2013 Apr 9.
6
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.
JAMA. 2012 Jul 4;308(1):43-9. doi: 10.1001/jama.2012.7304.
7
Immune correlates of herpes zoster in HIV-infected children and youth.
J Virol. 2012 Mar;86(5):2878-81. doi: 10.1128/JVI.06623-11. Epub 2011 Dec 14.
8
The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.
Arthritis Res Ther. 2011;13(5):R174. doi: 10.1186/ar3497. Epub 2011 Oct 24.
9
Perspectives on vaccines against varicella-zoster virus infections.
Curr Top Microbiol Immunol. 2010;342:359-72. doi: 10.1007/82_2010_12.
10
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.
J Infect Dis. 2010 Apr 1;201(7):1024-30. doi: 10.1086/651199.
本文引用的文献
1
Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.
J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):182-91. doi: 10.1097/QAI.0b013e31819550a4.
2
Primary vaccine failure after 1 dose of varicella vaccine in healthy children.
J Infect Dis. 2008 Apr 1;197(7):944-9. doi: 10.1086/529043.
3
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.
J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.
4
Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006.
Pediatrics. 2008 Jan;121(1):e150-6. doi: 10.1542/peds.2007-0564. Epub 2007 Dec 17.
5
Varicella vaccination in HIV-1-infected children after immune reconstitution.
AIDS. 2006 Nov 28;20(18):2321-9. doi: 10.1097/QAD.0b013e3280113f29.
6
Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.
J Infect Dis. 2006 Jul 15;194(2):247-55. doi: 10.1086/505149. Epub 2006 Jun 14.
7
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
N Engl J Med. 2005 Jun 2;352(22):2271-84. doi: 10.1056/NEJMoa051016.
8
Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy.
J Infect Dis. 2004 Jul 15;190(2):267-70. doi: 10.1086/422011. Epub 2004 Jun 9.
9
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
J Infect Dis. 2003 Nov 1;188(9):1336-44. doi: 10.1086/379048. Epub 2003 Oct 17.
10
Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization.
J Med Virol. 2003;70 Suppl 1:S38-41. doi: 10.1002/jmv.10318.
Zotero 插件